Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 3/2011

01-06-2011 | Case Report

Infliximab and brucellosis: not the usual suspects, this time

Authors: Ozgur Akgul, Salih Ozgocmen

Published in: Modern Rheumatology | Issue 3/2011

Login to get access

Abstract

Tumor necrosis factor (TNF) plays an important role in the host defense mechanism, and anti-TNF antibody therapies may increase the risk of serious infections. We herein report a case of 57-year-old male with rheumatoid arthritis who developed brucellosis during treatment with infliximab in combination with methotrexate and a low-dose steroid. Brucellosis should be kept in mind, particularly in endemic areas, in patients receiving anti-TNF therapy. Clinicians should be aware of brucellosis symptoms and ways of contamination and should warn their patients. Early diagnosis and rapid treatment may prevent a possible poor course of the disease in immunocompromised patients.
Literature
1.
Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006;6:91–9.PubMedCrossRef
2.
3.
Gur A, Geyik MF, Dikici B, et al. Complications of brucellosis in different age groups: a study of 283 cases in southeastern Anatolia of Turkey. Yonsei Med J. 2003;44:33–44.PubMed
4.
Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol. 2009;5:405–10.PubMedCrossRef
5.
Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168:4620–7.PubMed
6.
Jimenez FG, Colmenero JD, Irigoyen MV. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis. J Infect. 2005;50:370–1.PubMedCrossRef
7.
Papagoras CE, Argyropoulou MI, Voulgari PV, Vrabie I, Zikou AK, Drosos AA. A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab. Clin Exp Rheumatol. 2009;27:124–7.PubMed
8.
Duyur B, Erdem HR, Ozgocmen S. Paravertebral abscess formation and knee arthritis due to brucellosis in a patient with rheumatoid arthritis. Spinal Cord. 2001;39:554–6.PubMedCrossRef
9.
Ozgocmen S, Ardicoglu A, Kocakoc E, Kiris A, Ardicoglu O. Paravertebral abscess formation due to brucellosis in a patient with ankylosing spondylitis. Joint Bone Spine. 2001;68:521–4.PubMedCrossRef
10.
Geyik MF, Gur A, Nas K, et al. Musculoskeletal involvement of brucellosis in different age groups: a study of 195 cases. Swiss Med Wkly. 2002;132:98–105.PubMed
11.
Ozgocmen S, Ardicoglu O. Osteoarticular brucellosis. APLAR J Rheumatol. 1999;3:322–5.
Metadata
Title
Infliximab and brucellosis: not the usual suspects, this time
Authors
Ozgur Akgul
Salih Ozgocmen
Publication date
01-06-2011
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 3/2011
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-010-0388-1

Other articles of this Issue 3/2011

Modern Rheumatology 3/2011 Go to the issue

Case Report

Polymyositis associated with autoimmune hepatitis, primary biliary cirrhosis, and autoimmune thrombocytopenic purpura

Original Article

Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor

Original Article

Two subtypes of Churg–Strauss syndrome with neuropathy: the roles of eosinophils and ANCA

Original Article

Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice

Erratum

Erratum to: A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)

Case Report

Simultaneous presentation of hemophagocytic syndrome and mesenteric vasculitis in a patient with systemic lupus erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits